Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,994,700
-$4,410,374 QoQ
Shares Held
176,887
-45.6% QoQ
Ownership
0.148%
of shares outstanding
% of Portfolio
0.82%
of 13F equity value
Holder Rank
#60
of 197 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Decheng Capital LLC holds $731,749,065 across 14 Biotechnology names. NAMS ranks #12 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CGON |
CG Oncology, Inc.
|
6,371,669 | $452,707,082 | |
| 2 | NUVB |
Nuvation Bio Inc.
|
25,954,439 | $147,421,213 | |
| 3 | AARD |
Aardvark Therapeutics, Inc.
|
3,917,299 | $22,563,642 | |
| 4 | ACRS |
Aclaris Therapeutics, Inc.
|
4,041,736 | $21,380,783 | |
| 5 | UPB |
Upstream Bio, Inc.
|
2,724,868 | $18,856,086 | |
| 6 | RCUS |
Arcus Biosciences, Inc.
|
464,779 | $14,329,136 | |
| 7 | EQ |
Equillium, Inc.
|
4,447,308 | $14,231,385 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
52,667 | $9,863,475 |
All Filings in NAMS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,994,700 | 176,887 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $10,405,074 | 325,057 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $20,769,359 | 592,057 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $18,686,530 | 657,051 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $13,944,700 | 770,000 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $15,761,900 | 770,000 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $19,789,000 | 770,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $9,794,000 | 590,000 | Shares | Sole | 2024-11-15 | |
| 2024-06-30 | $7,684,000 | 400,000 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||